ARTES attends BioEurope Spring


ARTES attends BioEurope 2019

ARTES and Burnet Institute publish data on production and immunogenicity of malaria transmission-blocking vaccine candidates

ARTES Biotech­nol­o­gy and Bur­net Insti­tute recent­ly pub­lished data on the effi­cient pro­duc­tion of malar­ia vac­cine can­di­dates using virus-like par­ti­cles (VLP) pre­sent­ing malar­ia trans­mis­sion-stage anti­gens, which were capa­ble of induc­ing trans­mis­sion-block­ing anti­bod­ies.

ARTES attends BioEurope Spring 2019

Meet us at the Bio-Europe Spring 2018 tak­ing place in Vien­na, Aus­tria March 25 -27. Volk­er Jen­zelews­ki, Direc­tor Tech­nol­o­gy at ARTES, will be present in the One-on-One Part­ner­ing pre­sent­ing ARTES’ inno­v­a­tive range of cell line and process devel­op­ment solu­tions for bio-phar­ma­ceu­ti­cal and vac­cine prod­ucts.

SplitCore – the latest milestone in ARTES´ vaccine development offer

ARTES Biotech­nol­o­gy announces the acqui­si­tion of the unique Split­Core tech­nol­o­gy devel­oped by sci­en­tists at the Uni­ver­si­ty of Freiburg, Ger­many.

ARTES and Minapharm joint forces

ARTES Biotech­nol­o­gy GmbH, Ger­many, and Minapharm Phar­ma­ceu­ti­cals and Chem­i­cal Indus­tries S.A.E., Egypt, joint­ly announced today the for­ma­tion of a new strate­gic busi­ness pact, offer­ing pack­et solu­tion for bio­phar­ma­ceu­ti­cal process­es .


Aim of this new strate­gic busi­ness coop­er­a­tion is to joint­ly out-license com­bi­na­tions of ARTES’ and Minapharm’s respec­tive pro­pri­etary tech­nolo­gies and prod­ucts to third par­ties world­wide. Both part­ners own and con­trol tech­nolo­gies for micro­bial and mam­malian recom­bi­nant cell lines, process­es and prod­ucts.

The already exist­ing and estab­lished part­ner­ship among the com­pa­nies bases on a suc­cess­ful, long last­ing busi­ness rela­tion­ship. In this, ARTES acts as spe­cial­ist for micro­bial cell line and process devel­op­ment for recom­bi­nant pro­teins and Minapharm on the oth­er hand is the major play­er for pro­duc­tion and mar­ket­ing of bio-phar­ma­ceu­ti­cals in the MENA region.

With the com­bi­na­tion of ARTES’ and Minapharm’s busi­ness intel­li­gence and ser­vice solu­tions future clients will ben­e­fit from our lat­est, inno­v­a­tive devel­op­ments ”, Dr. Michael Pio­ntek, Man­ag­ing direc­tor of ARTES stat­ed, “and will get robust, proven man­u­fac­tur­ing expe­ri­ence and prod­uct reg­is­tra­tion.” Proven safe­ty and effi­ca­cy of prod­ucts will team up with high yield and low cost man­u­fac­tur­ing tech­nol­o­gy.

The estab­lished alliance with ARTES con­tin­u­ous­ly con­firms Minapharm’s posi­tion as a region­al biotech leader. Our emer­gence as such con­tributes to a rad­i­cal shift in both inno­va­tion and afford­abil­i­ty of bio­phar­ma­ceu­ti­cals as a func­tion of time. We have been able to demon­strate the via­bil­i­ty of our strat­e­gy to offer patients in the devel­op­ing world with a time­ly ben­e­fit of nov­el ther­a­peu­tic pro­teins. Our bio­phar­ma­ceu­ti­cal pipeline port­fo­lio reflects great poten­tial to expand our strat­e­gy and offers solu­tions for the man­age­ment of med­ical emer­gen­cies. We are glad that ARTES is shar­ing our vision” said Frank Mueller, Senior Man­ag­er Bio­phar­ma­ceu­ti­cal Projects of Minapharm.

ARTES successfully completed EU funded project Plurivax

ARTES Biotech­nol­o­gy explored very effec­tive in a SME con­sor­tium vac­cine devel­op­ments for vet­eri­nary appli­ca­tions.
Under the titel: “ERA-Net Euro­Trans­Bio-8: PLURIVAX, devel­op­ment of a virus-like-par­ti­cle (VLP) based vac­cine plat­form and sta­ble for­mu­la­tion espe­cial­ly suit­ed for the vet­eri­nary appli­ca­tions, the EU coop­er­a­tion was part of the 8th Euro­Trans­Bio call and was fund­ed in the time peri­od from June 2014 to Novem­ber 2017 by the Ger­man Fed­er­al Min­istry of Edu­ca­tion and Research (BMBF) and the Flan­ders (Bel­gium) agency for Inno­va­tion by Sci­ence and Tech­nol­o­gy (IWT).
For the devel­op­ment of vac­cines for human appli­ca­tions it is state of the art to use virus-like par­ti­cles (VLPs) as a vehi­cle. The use of these par­ti­cles has the advan­tage that they as such not being infec­tious but that they trans­port for­eign anti­gens in an ide­al way to the immune sys­tem. These very effec­tive and sim­ple mech­a­nism was the back­bone of the PLURIVAX project.
“As ini­tial nucle­us our pro­pri­etary VLP plat­form METAVAX® was tak­en. This plat­form has already been applied to the devel­op­ment of adju­vant-free vac­cine can­di­dates against dif­fer­ent human relat­ing dis­eases like flu, malar­ia and HIV”, Michael Pio­ntek, man­ag­ing direc­tor of ARTES stat­ed. “Our expres­sion host, the methy­lotroph­ic yeast Hansenu­la poly­mor­pha, is the pre­ferred tech­nol­o­gy for afford­able mass vac­ci­na­tion and is rec­om­mend­ed by the WHO for mass vac­ci­na­tions. Com­bi­na­tion of our both plat­forms build an excel­lent approach to low-cost mass pro­duc­tion of safe and effec­tive vac­cines.”
ARTES chose eight dif­fer­ent, large mol­e­c­u­lar weight anti­gens derived from four animal‑ infect­ing virus­es. The bovine viral diar­rhea virus (BVDV) as an impor­tant pathogen of cat­tle, also infect­ing sheep and pigs. The clas­si­cal swine fever virus (CSFV), which is acknowl­edged as a glob­al threat for swine and is list­ed as noti­fi­able ani­mal dis­eases by the World Orga­ni­za­tion for Ani­mal Health. The feline leukemia virus (FeLV) as a retro­virus threat­en­ing domes­tic cats and the west nile virus (WNV) which is a mos­qui­to vec­tor trans­mit­ted zoonot­ic virus of the Fla­viviri­dae fam­i­ly. WNV cir­cu­lates in birds as nat­ur­al hosts but can be trans­mit­ted to mam­mals includ­ing humans caus­ing west nile fever.
First results were released in a sci­en­tif­ic paper under the title “Estab­lish­ment of a yeast-based VLP plat­form for anti­gen pre­sen­ta­tion” (Wet­zel et al. Microb Cell Fact (2018) 17:17 )
and more infor­ma­tion could be get on‑0868-0

Future steps are, that in close dis­cus­sions with glob­al vet­eri­nary vac­cine man­u­fac­tur­er, ARTES’ explores the com­mer­cial appli­ca­tion of the results and of the plat­form in gen­er­al.

ARTES attends Bio-Europe Spring 2018

Meet us at the Bio-Europe Spring 2018 tak­ing place in Ams­ter­dam March 12 -14. Michael Pio­ntek, Man­ag­ing Direc­tor at ARTES, will be present in the One-on-One Part­ner­ing pre­sent­ing ARTES’ inno­v­a­tive range of cell line and process devel­op­ment solu­tions for bio-phar­ma­ceu­ti­cal and vac­cine prod­ucts. Con­tact us pre­vi­ous­ly for orga­niz­ing a per­son­al meet­ing or drop us a notice via the part­ner­ing sys­tem. We look for­ward to meet­ing you!